Ginkgo Bioworks announced that it would provide autonomous laboratory time and protein testing services to NSF X-Labs research teams. The support aims to reduce the burden of assembling equipment in-house and make it easier to turn research proposals into experiments.
The $1.5 billion scale of X-Labs as a whole does not represent a payment to Ginkgo alone. Nor does this announcement establish individual access terms or rights to resulting outputs and data. As an example of support that provides experimental capacity as well as research funding, it connects with our card on the business of scientific AI ↗. Announcement ↗
Evidence & reading
Public sources checked for this edition. Linked pages may subsequently change.
- Ginkgo Bioworks to provide autonomous lab access to NSF X-Labs researchers ↗Ginkgo Bioworks / Business Wire · 2026-10-08
READER DISCUSSION
What does this change for you?
A question, a different reading, or a source we should consider. A short comment is welcome.
Comments are public only after editorial review. Comments, likes and reports are for people aged 18 or older. Sign-in is required; you choose a public display name. Reviews are not continuous. Discussion rules
Loading discussion…
Also in this issue
Contents →Commercialization
Changing treatment before scans show progression: a new relationship between breast cancer drugs and blood tests
A blood test can help decide when to switch breast cancer treatment. What do the comparative and confirmatory trials tell us about this test–drug strategy?
R&D Allocation
Does an antibody that binds well make a good development candidate?
Improving an antibody, selecting one and deciding to develop it are different tasks. A blinded benchmark helps clarify what buyers of research AI should evaluate.
Frontier Science
Can the same information remain readable as neural activity changes?
Even when the same cells are tracked over time, their activity changes. Long-term mouse recordings raise questions about preserved population relationships and adaptive readout.
Commercialization
BioNTech: mRNA cancer immunotherapy combination misses PFS endpoint; survival evaluation continues
BNT113 plus pembrolizumab adds a clinical outcome to the combination-development record. The prespecified survival assessment continues.